Summit Therapeutics Inc. Current Tax Expense Income
Summit Therapeutics Inc. (SMMT) reported Current Tax Expense Income of -GBP 1.19 million for the 3-month period ending 2020-03-31, per its 6-K filed 2020-06-02.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:CurrentTaxExpenseIncome · last filed 2020-06-02
- Summit Therapeutics Inc. current tax expense income for the quarter ending 2020-03-31 was -1.19M GBP.
- Summit Therapeutics Inc. current tax expense income for the quarter ending 2019-10-31 was -696.00K GBP.
- Summit Therapeutics Inc. current tax expense income for the quarter ending 2019-07-31 was -1.03M GBP, a 197.54% decline year-over-year.
- Summit Therapeutics Inc. current tax expense income for the quarter ending 2019-04-30 was -811.00K GBP.
| Period end | Current Tax Expense Income 3 month | Current Tax Expense Income 6 month | Current Tax Expense Income 9 month | Current Tax Expense Income 11 month | Current Tax Expense Income 12 month | Current Tax Expense Income 12 month as first filed |
|---|---|---|---|---|---|---|
| 2020-03-31 | -1.19M GBP 6-K · filed 2020-06-02 | |||||
| 2019-12-31 | -3.52M GBP 20-F · filed 2020-04-30 | |||||
| 2019-10-31 | -696.00K GBP 6-K · filed 2019-12-17 | -1.73M GBP derived: sum of 2 quarters · filed 2019-12-17 | -2.54M GBP 6-K · filed 2019-12-17 | |||
| 2019-07-31 | -1.03M GBP 6-K · filed 2019-10-11 | -1.84M GBP 6-K · filed 2019-10-11 | ||||
| 2019-04-30 | -811.00K GBP 6-K · filed 2019-06-12 | |||||
| 2019-03-31 | -800.00K GBP 6-K · filed 2020-06-02 | |||||
| 2019-01-31 | -228.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -1.40M GBP derived: sum of 2 quarters · filed 2020-04-30 | -340.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | -1.29M GBP 20-F · filed 2020-04-30 | 1.29M GBP 20-F · filed 2019-03-29 | |
| 2018-10-31 | -1.17M GBP 6-K · filed 2019-12-17 | -112.00K GBP derived: sum of 2 quarters · filed 2019-12-17 | -1.06M GBP 6-K · filed 2019-12-17 | -866.00K GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-07-31 | 1.06M GBP 6-K · filed 2019-10-11 | 110.00K GBP 6-K · filed 2019-10-11 | 302.00K GBP derived: sum of 3 quarters · filed 2020-04-30 | -1.17M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-04-30 | -946.00K GBP 6-K · filed 2019-06-12 | -754.00K GBP derived: sum of 2 quarters · filed 2020-04-30 | -2.23M GBP derived: sum of 3 quarters · filed 2020-04-30 | -3.51M GBP derived: sum of 4 quarters · filed 2020-04-30 | ||
| 2018-01-31 | 192.00K GBP derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -1.28M GBP derived: sum of 2 quarters · filed 2020-04-30 | -2.56M GBP derived: sum of 3 quarters · filed 2020-04-30 | -3.77M GBP 20-F · filed 2020-04-30 | 3.77M GBP 20-F · filed 2018-04-13 | |
| 2017-10-31 | -1.47M GBP 6-K · filed 2018-12-11 | -2.76M GBP derived: sum of 2 quarters · filed 2018-12-11 | -3.96M GBP 6-K · filed 2018-12-11 | |||
| 2017-07-31 | -1.28M GBP 6-K · filed 2018-09-20 | -2.49M GBP 6-K · filed 2018-09-20 | ||||
| 2017-01-31 | 4.25M GBP 20-F · filed 2019-03-29 | |||||
| 2016-01-31 | 2.97M GBP 20-F · filed 2018-04-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |